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Key Points 
 
The incidence of AMD is unknown in Africa  
 
A population-based six-year cohort study of adult Kenyans (aged 50 and over) was 
conducted and the six-year weighted (for loss to follow-up) cumulative incidence of 
early AMD was 164.2 per 1000 people 
 
AMD will become a greater public health concern in the future with population 
ageing and as other more treatable eye conditions come under control. 
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Abstract  
 
Importance: The incidence of age-related macula degeneration (AMD) is unknown in 
Africa. 
 
Objectives: To estimate the six-year cumulative incidence and progression of AMD in 
older adults (≥ 50 years) in Nakuru, Kenya. 
 
Design, Setting and Participants: A population-based cohort with six-year follow-up 
of 1,626 participants seen at baseline (26-January-2007 to 11-November-2008) 
and follow-up (7-January-2013 to 12-March-2014) with retinal images.  
Random cluster sampling with probability-proportionate-to-size procedures were 
used to select a representative cross-sectional sample of adults aged ≥50 years in 
2007-8. A six-year follow-up was undertaken in 2013-14. On both occasions a 
comprehensive ophthalmic examination was performed including LogMAR visual 
acuity, digital retinal photography and grading of images at Moorfields Eye Hospital 
Reading Centre. Data were collected on general health and risk factors. 
 
Main Outcome and Measures: Incident AMD in those with no AMD at baseline and 
progression from early to late AMD. 
 
Results: 1,453 (50%) of the people at-risk of AMD were followed up after six-years 
(mean age (SD) 60.7 (8.2), Female 49.5%, Ethnicity: 63.2% Kikuyu, 25.3% Kalenjin, 
12.4% Other); 1,282 had data on AMD status at follow-up. Of these, 202 developed 
early AMD and no participants developed late AMD. The six-year weighted (for loss 
to follow-up) cumulative incidence of early AMD was 164.2 per 1000 people (95% CI: 
136.7-195.9). Two cases with baseline early AMD from the 142 at-risk had developed 
late AMD at follow-up, with a six-year cumulative incidence of progression from 
early to late AMD of 24.5 per 1000 people (95%CI: 5.0-111.7). Cumulative incidence 
of AMD increased with age (80+: 1.8, 95%CI (0.9,3.5) vs. 50-59) and was higher in 
women (Female: 1.6, 95%CI (1.2,2.1) vs.  Male)  and people with diabetes (Diabetes: 
1.7, 95%CI (1.0,2.8) vs. No diabetes.  
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Conclusions and Relevance: We estimate that in Kenya, over 100,000 new cases 
of AMD, mainly early AMD, will develop every year in people aged >=50 years, 
although a 50% loss to follow-up and wide confidence intervals for progression 
to late AMD limit definitive conclusions from these findings. 
 
Financial Disclosure(s): The authors have no proprietary or commercial interest in 
any of the materials discussed in this article. 
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Introduction 
 
Age-related macular degeneration (AMD) is a progressive degenerative disease 
affecting the central retina and is highly associated with age.1 Advanced AMD 
including geographic atrophy (late dry) and neovasuclar AMD (wet) lead to central 
vision loss. In the early dry form of the disease, deposits known as drusen are 
layered between the retina and choroid and subtypes of drusen (based on size and 
morphology) form part of the more detailed classifications. AMD is a leading cause 
of visual impairment and blindness in populations living in high-income countries,2 
but there is a paucity of available data from low and middle-income countries 
(LMICs),3 including within Sub-Saharan Africa. However, a recent systematic review 
found that overall posterior-segment disease is a common cause of visual 
impairment within Sub-Saharan Africa,4 and a survey in Kenya showed that one in 
ten people aged 50 years and above had signs of AMD.5 
 
Estimation of the incidence and progression of AMD and associated sight loss is 
important for planning of services. Treatment for neovascular AMD is currently 
possible within well-established health systems, but infrequently available in LMICs. 
It is therefore important to be able to identify people at high risk of AMD in order to 
consider targeted approaches for prevention and/or treatment. Furthermore, 
rehabilitation services need to be planned for people developing visual loss as a 
result of AMD. Unfortunately, data to plan these services are currently lacking. The 
incidence of AMD has been investigated in seven cohort studies of eye disease 
worldwide,6-16 with no data from the African continent. There are large variations in 
the prevalence, phenotypes and incidence of AMD in different populations, 6-16 
making extrapolation of findings from studies in other regions of the world to an 
African setting difficult.  
 
The aim of this current study was to estimate the six-year cumulative incidence of 
AMD in Nakuru, Kenya, as well as identify risk factors for incident disease. 
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Methods/Design 
 
The following examination protocols were implemented at both baseline and follow-
up with detailed methodology available elsewhere21 and in the supplementary 
material: 
 
Ophthalmic and General Examination 
All participants underwent LogMAR visual acuity (VA) testing on each eye separately 
and corrected VA when <20/40 Snellen equivalent.  
 
Detailed interviews were undertaken in the local language covering demographic 
details, information on risk factors, socio-economic status (SES) and full past medical 
history.  
 
A nurse recorded the blood pressure, weight, height and waist and hip 
circumferences. 
 
Participants had two non-stereoscopic digital 450 fundus photographs (one disc and 
one macula centred) taken per eye by an ophthalmic clinical officer. Digital images 
were graded at an approved grading centre. 
 
The senior grader (NS) graded all images for the presence of AMD. All eyes classified 
as having late-stage AMD were adjudicated by the MEHRC clinician (TP). The 
adjudicator also graded 5% of randomly selected images to ensure quality control..  
 
 
 
Definitions of AMD Used 
A modified version of the International Classification and grading system for age-
related maculopathy and AMD was used for image grading at baseline and follow-
up.24 Drusen were categorized based on size, uniformity of colour and margins. 
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Patients were classified into hard or soft drusen categories: small drusen <63μm 
were considered to be hard. Large drusen with a uniform density, sharp margins, and 
a nodular surface texture were placed in the soft distinct category, whereas those 
without sharp margin were classified as indistinct. When end-stage disease was 
apparent, patients were classified as having Geographic Atrophy (GA) in the 
presence of well-demarcated regions with diameters >175μm, within which large 
choroidal vessels were clearly visible, owing to the atrophy of the overlying 
choriocapillaris and Retinal Pigment Epithelium. Neovascular AMD was graded as 
present when exudative features, such as serous fluid, haemorrhage, lipid exudates 
or fibrosis were seen to be originating primarily from the subretinal, pigment and 
epithelial tissue layers.   
 
Case definitions were based on the eye with more severe status if both eyes were 
gradable and on the gradable eye if only one was gradable. “Early AMD” was defined 
as the presence of large, soft drusen, the presence of pigmentation >63μm, and 
“Late AMD” the presence of GA or neovascular AMD.  
 
Incident AMD was defined on the absence of AMD features at baseline on retinal 
images and subsequent presence of these features at follow-up. Incident Late AMD 
was defined as the combination of i) no or Early AMD at baseline and ii) signs of Late 
AMD at follow-up.  
 
 
 
Dealing with loss to follow-up 
Logistic regressions corrected for the survey-design were used to calculate p-values 
to assess differences between participants seen and those lost to follow-up (LTFU) 
and those known to have died.  
 
An inverse probability-weighting (IPW) model was used to allow estimation of 
cumulative incidence while accounting for those LTFU. Those who had died between 
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baseline and follow-up were excluded from the analysis. Multivariable logistic 
regression was used to identify independent baseline covariates associated with 
LTFU. Covariates for which there was evidence of association with the outcome 
(p<0.1) were kept in a multivariable model. Individuals without a complete set of the 
baseline covariates included in the final multivariable model were excluded from any 
estimations based on the weighted analysis. From this final model, the probability of 
being followed was estimated, based on the presence or absence of each of these 
baseline covariates. The inverse of this probability formed the weighting to be 
applied in order to account for those LTFU. 
 
The final step was to exclude those individuals LTFU from the analysis, and apply the 
IPW to account for those LTFU.  A sensitivity analysis for this approach involved a 
complete records analysis (i.e. only including those people who had complete 
records for outcome and all variables in the analysis).  
 
Cumulative incidence estimation 
The six-year cumulative incidence of AMD was estimated by dividing the total 
(weighted) number of individuals who were classified as having AMD at follow-up by 
the (weighted) number AMD free at baseline and examined at follow-up. The six-
year cumulative incidence was then used to estimate the expected number of new 
AMD cases per year. First, the size of the at-risk population in Kenya was estimated, 
using the baseline prevalence of AMD from this cohort and the 2015 Kenyan 
population estimates for those over 50 years old. The six-year incidence was then 
multiplied by this at-risk population and divided by six, with the assumption that 
cumulative incidence was constant over time. Annual cumulative incidence was also 
estimated separately for men and women and in ten-year age categories (50-59, 60-
69, 70-79 and 80+). 
 
The incidence of progression from Early AMD to Late AMD was calculated by 
examining participants with Early AMD at baseline who were followed up and had a 
valid AMD status at follow-up. 
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Assessing risk factors associated with AMD incidence 
The age-adjusted association between AMD incidence and each covariate was 
estimated using a Poisson regression model. A multivariable model was created 
using backward stepwise selection, using the likelihood ratio test and a threshold of 
p<0.05 for retention of a variable in the model.   
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Results 
 
At baseline, 4,414 participants had a complete assessment, of whom 3,304 (75%) 
had an AMD assessment from retinal imaging (Figure 1). Of these, 404 (12%) had 
AMD at baseline, the majority (n=366; 91%) had early AMD and 38 (9%) had late 
AMD. A further 2,900 participants did not have AMD at baseline and were therefore 
at risk of developing AMD at follow-up.5 
 
Characteristics of participants and non-participants at six-year follow-up are shown 
in Table 1. Non-participants were divided into those who had died, and those who 
had not but did not attend the examination clinic (e.g. due to mass displacement in 
the period of post election violence after the baseline study period) and/or those 
without a valid AMD assessment (e.g. cataract obstructing a view of the retina). 
Compared with those followed-up, participants who had died during follow-up were 
older, more likely to be male, to have lower education levels and higher systolic 
blood pressure and have diabetes, but had lower BMI. Compared with participants 
seen, those lost to follow-up were less likely to be Kikuyu or Kalenjin speakers, had 
lower levels of education, and were more likely to be from urban areas and be from 
either the highest or lowest socioeconomic quartile. People seen at follow-up were 
less likely to have VI at baseline (3.7%) compared with either those who died before 
follow-up (13.3%) or those not seen at follow-up (7.0%). 
 
In total, 1,453 (50%) of the people at-risk of AMD were followed up after six-years 
(Figure 1), and 1,282 had data on AMD at follow-up. Of these, 202 developed early 
AMD and no participants developed late AMD. The six-year cumulative incidence of 
early AMD, after taking account of LTFU by using IPWs, was 164.2 per 1000 people 
(95% CI: 136.7-195.9).  
 
In addition, 366 participants with early AMD were at risk of progressing to late AMD 
at follow-up, of whom 173 were followed up and 142 had a valid AMD assessment 
(25 of 31 who did not have an AMD assessment had a lens opacity obscuring the 
retinal images). Two cases with early AMD from the 142 at-risk had developed late 
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AMD at follow-up (Figure 1), giving a six-year cumulative incidence of progression 
from early to late AMD of 24.5 per 1000 people (95%CI: 5.0-111.7).   
 
Of the 38 people with late AMD at baseline, 17 (45%) participants were followed up, 
five (13%) died and 16 (42%) were not located for follow-up. Of the 17 followed up, 
four did not have a valid AMD assessment (due to obstructing lens opacities), 11 
remained classified as late AMD, and two as “critical eye difficult to grade due to 
image quality, but most likely to be stable end-stage” AMD. The visual status at 
baseline and follow-up is shown in eTable1. 
 
 
 
Cumulative incidence of AMD  (80+: 243.8 per 1,000 [115.8-442.4] vs. 50-59: 
139.3 per 1,000 [105.3-181.9]) strongly correlated with age (Table 2). The 
cumulative incidence of AMD was higher for females than males in each age group 
(Female: 197.0 per 1,000 [156.7-244.7] vs. Male: 130.5 per 1,000 [104.1-
162.4]), with an overall six-year cumulative incidence of 197 new cases per 1,000 
people (95%CI: 157 to 245) in females compared to 131 new cases per 1,000 people 
(95%CI: 104 to 162) in males, giving an unadjusted risk ratio of 1.51 (95% CI: 1.14 to 
2.00). For each increase in age category the risk ratio was estimated to be 1.19 (95% 
CI: 1.00 to 1.42). 
 
Based on extrapolations of these results to census data and population estimates in 
2015 (assuming incident cases annually is proportional to the cumulative incidence), 
we estimate that in Kenya 103,070 new cases of AMD (at any severity) develop every 
year in the people aged ≥50 years, of whom 65,720 (64%) are among women (Table 
3).  
 
Specific features of AMD that appear or regress over the study period were recorded 
(eTable 2). Small drusen were noted to have a six-year cumulative incidence of 
59.1% (95%CI: 53.7-64.3%) and a cumulative risk of 24.1% (95%CI:20.6-28.0%) for 
regression. Hyperpigmentation and hypopigmentation both had a high cumulative 
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risk of resolution over the six-year follow-up period (77.0%; 95%CI:59.5-88.4% and 
58.1%; 95%CI:39.7-74.4% respectively) but low incidence (3.5%; 95%CI:2.5-5.0% and 
5.0%; 95%CI:3.5-7.1% respectively). 
  
Multivariable analysis of factors associated with incident AMD indicated an 
increasing incidence of AMD with older age (p-value (for trend) = 0.02), female 
gender (p=0.001) and having diabetes mellitus (p=0.04) (Table 4).  
Of those who developed incident VI in the cohort (n=234), 162 had an available AMD 
assessment at follow-up (69%). Of the 162 cases, 52 (32%) had AMD and three of 
these were classified as blind. It was not possible to infer whether vision loss was 
solely due to AMD or a combination of other ocular co-morbidities. Change in vision 
category from baseline to follow-up in all those with a valid AMD status at baseline 
and follow-up is described in eTable3. 
202 participants developed incident AMD in the cohort, of whom 192 had normal 
vision at baseline. 27 (14%) of the 192 developed visual impairment by follow-up. 
1,080 participants did not develop AMD with 1,040 of this group having normal 
vision at baseline. Of these 1,040, 83 (9%) developed VI. 
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Discussion 
 The Nakuru Eye Disease Cohort Study provides longitudinal data on AMD from 
sub-Saharan Africa from a population-based cohort. While there is 50% loss to 
follow-up, and few cases developing late AMD (resulting in wide confidence 
intervals for that outcome), there are limited data on these outcomes from this 
region. With those caveats in mind, over six years, one in six adults over the age of 
50years developed early manifestations of AMD with women having a higher 
incidence than men. Increasing age was strongly related to both the prevalence and 
incidence of AMD. The majority of incident cases of AMD were defined on the basis 
of the development of large drusen (>64μm). Late AMD was infrequent at baseline 
and consistent with this pattern, only two cases of incident late AMD were found at 
follow-up. Both incident cases developed in people with early AMD at baseline, and 
no case was identified that progressed from no AMD to late AMD. 
Our data estimate a higher incidence of AMD than other (non-African) cohort studies 
of eye disease (eTable 4). A likely explanation is that the Nakuru Cohort includes only 
people aged ≥50years, similar to the next two highest cumulative annual incidence 
estimates, which were also from older samples in Copenhagen 6 and Reykjavik 11. 
Furthermore, in the Nakuru study there was a higher incidence of early AMD and a 
lower incidence of late AMD compared to other populations. This observation is 
consistent with the baseline finding, which indicated a comparatively high 
prevalence of early AMD but low prevalence of late AMD 5, 6-16 The two participants 
who progressed from early to late AMD were both above the age of 80, and since 
few people in the Nakuru cohort were in this age group it may explain the low 
incidence of late AMD, since age is the leading risk factor for incident AMD. 
A high prevalence of early AMD at baseline and high incidence of early AMD at 
follow-up may suggest that the population under investigation has a higher risk of 
developing AMD. The relatively high prevalence and incidence may possibly be 
attributed to greater ultra violet light exposure, earlier biological aging, greater 
genetic predisposition or greater susceptibility to inflammatory processes, which 
have been attributed with AMD.25 The proportion of people suffering vision loss due 
to AMD is relatively low as a factor of overall vision loss being primarily due to 
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conditions such as cataract that are largely under control in more developed health 
systems. Of those with AMD, 14% developed VI over the six-year study period 
compared to 9% over 14 years in a well-developed health system in Copenhagen. It 
should be noted however that this VI cannot be attributed to AMD alone.  
 
Strengths and limitations 
This study was conducted under challenging circumstances with limited 
infrastructure. It provides independently graded digital image based analysis of AMD 
in an east African cohort that is diverse and largely representative of the population 
from which it was sampled. Detailed ophthalmic, demographic and anthropometric 
assessment of each participant has enabled valuable analyses of associations and 
risk factors.  
Despite these strengths, limitations in the current study may have contributed to an 
underestimation of the true incidence of AMD and AMD lesions. First, the main 
limitation of our study is the large loss of participants at follow-up. Of the 4,414 
persons who participated in the baseline study, only 2,171 persons participated in 
the follow-up examination, of whom 1,424 had gradable images at baseline and 
follow-up, the majority being excluded from analysis as a result of camera failure at 
baseline, lack of electricity access and/or ungradable images due to media opacities. 
Only those who had gradable images at both time points were included in the 
analysis.    
A complete case record analysis was conducted without weighting for LTFU 
(eTable5) with results very similar to using the IPW modeling (Table 2). The results 
were largely similar with a possible underestimation of the incidence in females 
when the LTFU is not taken in to account.  
Second, changes in procedures between the baseline and follow-up examination 
(different retinal camera) may have introduced bias. Change in cameras may have 
caused images with different colour profiles and saturation levels resulting in 
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different abilities to detect AMD features (e.g. drusen and pigment).  Furthermore, 
the lack of stereo photographs meant cases of retinal elevation may have been 
overlooked. These factors may have resulted in bias toward an underestimation of 
the incidence of subtle early AMD lesions such as small drusen or an over estimation 
of pigmentation attributed to AMD. Comparison images between cameras on the 
same study participants at baseline and follow-up is shown in eTable6. Overall image 
quality was considered equivalent at the two time points in those with clear media 
(i.e. no lens or corneal opacity). 
Third, survival bias may have caused an underestimation of the true incidence of late 
AMD if those who died before the follow-up and had experienced advanced AMD 
lesions after the first examination and it is possible that those with worsening 
disease were more likely to attend for follow up. 
The low prevalence of late AMD at baseline and low incidence can, in part, be 
attributed to a lack of older people in this study population with a younger expected 
mortality than other populations with data on AMD incidence.  
Classification bias may also be contributing to the estimates and histological studies 
would be required to confirm if the manifestations being attributed to AMD are 
consistent with other populations.  
Conclusions 
We estimate that in Kenya, over 100,000 new cases of AMD, mainly early AMD, 
will develop every year in people aged >=50 years, although a 50% loss to 
follow-up and wide confidence intervals for progression to late AMD limit 
definitive conclusions from these findings. The AMD in this population was found 
to be phenotypically different than in prior studies5. However, since the relatively 
high incidence was restricted to occurrence of early AMD this may not have major 
implications for clinical practice given the low number with associated visual loss.   
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Figure 1. Participant flowchart  
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Table 1: Baseline characteristics of all individuals with no AMD at baseline according 
to availability of AMD status at 6 year follow up (N=2900) 
 
  Participants Non-participants or not included 
in analysis 
Baseline Characteristics Missing 
Values 
Followed-up 
n=1,282 
(44.2%) 
 
Not followed-up 
Alive/Unknown/ 
AMD status 
missing n=1,393 
(48.0%) 
Deceased 
n=225 
(7.8%%) 
Age in years, mean (SD) 0 60.7 (8.2) 61.8 (9.8) 68.5 (12.0)** 
Systolic BP in mmHg, mean (SD) 
26 138.4 (23.6) 139.3 (23.6) 
143.3 
(28.7)** 
Diastolic BP in mmHg , mean (SD) 26 83.1 (13.0) 82.6 (13.1) 82.4 (16.0) 
Random Blood Glucose, mean (SD) 79 5.2 (2.3) 5.2 (2.2) 5.6 (3.3)** 
Sex, % (n) Female 
0 635 (49.5%) 686 (49.2%) 
139 
(61.8%)** 
Male   647 (50.5%) 707 (50.8%) 86 (38.2%) 
BMI, % (n) Underweight (<18.5kg/m2) 29 139 (10.9%) 188 (13.7%) 52 (23.2%)** 
Normal (18.5-24.99kg/m2)   648 (50.7%) 674 (49.2%) 113 (50.4%) 
Overweight (25-29.99kg/m2)   307 (24.0%) 321 (23.4%) 40 (17.9%) 
Obese (30+kg/m2)   184 (14.4%) 186 (13.6%) 19 (8.5%) 
Vision status impaired 
(<6/12 better eye), % (n) 
Normal 
18 1233 (96.3%) 1279 (93.0%)* 
195 
(86.7%)** 
Impaired   48 (3.7%) 97 (7.0%) 30 (13.3%) 
Tribe, % (n) Kikuyu 0 799 (62.3%) 782 (56.1%)* 152 (67.6%) 
Kalenjin   324 (25.3%) 313 (22.5%) 52 (23.1%) 
Other   159 (12.4%) 298 (21.4%) 21 (9.3%) 
Education, % (n) None 21 119 (9.3%) 163 (11.9%)* 15 (6.7%)** 
Primary   345 (26.9%) 432 (31.4%) 91 (40.6%) 
Secondary   677 (52.8%) 608 (44.3%) 94 (42.0%) 
Higher   140 (10.9%) 171 (12.4%) 24 (10.7%) 
Residence, % (n) Rural 0 937 (73.1%) 763 (54.8%)* 161 (71.6%) 
Urban   345 (26.9%) 630 (45.2%) 64 (28.4%) 
SES Quartile, % (n) Lower 34 266 (20.9%) 324 (23.7%)* 66 (29.5%) 
Middle lower   347 (27.2%) 304 (22.2%) 55 (24.6%) 
Middle upper   345 (27.1%) 342 (25.0%) 60 (26.8%) 
Upper   317 (24.9%) 397 (29.0%) 43 (19.2%) 
Smokers, % (n) Never 15 861 (67.2%) 980 (71.1%)* 134 (59.6%) 
Former   104 (8.1%) 124 (9.0%) 22 (9.8%) 
Current   317 (24.7%) 274 (19.9%) 69 (30.7%) 
Alcohol, % (n) Never 23 524 (40.9%) 512 (37.3%) 61 (27.2%)** 
Former   549 (42.9%) 595 (43.3%) 116 (51.8%) 
Current   207 (16.2%) 266 (19.4%) 47 (21.0%) 
 
* P-value <0.05 for association between the baseline characteristic and the odds being followed-up, 
amongst all participants identified as non-AMD at baseline and not known to be deceased at follow 
up. 
** P-value <0.05 for association between the baseline characteristic and the odds of dying during the 
follow up period, amongst all participants identified as non-AMD at baseline, excluding the group who 
were not followed up. 
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Table 2. Age-Gender–Specific six-year cumulative incidence of AMD among the 
Nakuru Eye Disease Cohort Study Participants 
 
 Male Female Overall 
Age Group 
(years) 
N 
(Cases / 
at risk) 
Risk per 1,000/6yrs 
(95%CI)* 
N 
(Cases / 
at risk) 
Risk per 
1,000/6yrs 
(95%CI) 
N 
(Cases / at 
risk) 
Risk per 1,000/6yrs 
(95%CI) 
50-59 29 / 288 98.2(64.8,146.1) 60 / 369 172.7(129.4,226.6) 89 / 657 139.3(105.3,181.9) 
60-69 33 / 221 146.6(103.6,203.4) 38 / 197 214.5(152.0,293.7) 71 / 418 179.9(142.8,224.3) 
70-79 20 / 104 184.6(121.3,270.9) 13 / 66 193.0(109.3,318.0) 33 / 170 188.0(138.2,250.6) 
80+ 4 / 22 148.1(51.0,360.0) 5 / 15 378.8(132.6,708.7) 9 / 37 243.8(115.8,442.4) 
All ages 86 / 635 130.5(104.1,162.4) 116 / 647 197.0(156.7,244.7) 202 / 1282 164.2(136.7,195.9) 
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Table 3. Extrapolated number of new adults, per year, aged 50 years and over in 
Kenya developing AMD, based on incidence data (adjusted to take account of loss to 
follow up) and estimates of the population in Kenya by age group in 2015. 
 
  Male Female Overall 
Age Group 
(years) 
Extrapolated 
number 
Lower 
(95%CI) 
Upper 
(95%CI) 
Extrapolated 
number 
Lower 
(95%CI) 
Upper 
(95%CI) 
Extrapolated 
number 
Lower 
(95%CI) 
Upper 
(95%CI) 
AMD  
50-59 16460 10860 24500 31520 23630 41360 48770 36890 63700 
60-69 12280 8680 17040 21800 15450 29860 33450 26540 41690 
70-79 6650 4370 9750 7720 4370 12710 14550 10700 19400 
80+ 1520 520 3710 4550 1590 8520 5520 2620 10020 
All ages over 
50 
38280 30530 47650 65720 52270 81620 103070 85800 123020 
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Table-4. Age-adjusted and multivariable analysis of a number of baseline co-
variables and incident AMD in the Nakuru Eye Disease Cohort Study. (At risk = No 
AMD at baseline, incident AMD = early or late AMD at follow up)  Sample n=1,282. 
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 Study sample, n = 1,282 
 
At risk of 
AMD (n) 
Incident AMD 
Risk per 1,000/6yrs 
(95%CI) 
Age adjusted risk 
ratio (95%CI) 
Multivariable 
adjusted risk 
ratio (95%CI)* 
Age 
50-59 657 89 139.3(105.3,181.9) Baseline p=0.16 Baseline p=0.07 
60-69 418 71 179.9(142.8,224.3) 1.3(1.0,1.7) 1.3 (1.0,1.7) 
70-79 170 33 188.0(138.2,250.6) 1.4(0.9,1.9) 1.5 (1.0,2.1) 
80+ 37 9 243.8(115.8,442.4) 1.8(0.8,3.7) 1.8 (0.9,3.5) 
Gender 
Male 635 86 130.5(104.1,162.4) Baseline p=0.002 Baseline p=0.001 
Female 647 116 197.0(156.7,244.7) 1.6(1.2,2.1) 1.6 (1.2,2.1) 
BMI (4 missing values) 
Underweight 139 25 191.3(127.2,277.4) Baseline p=0.84  
Normal 648 98 160.1(129.9,195.7) 0.8(0.5,1.3)  
Overweight 307 49 159.4(113.0,220.1) 0.9(0.6,1.4)  
Obese 184 30 169.1(119.0,234.6) 0.9(0.6,1.6)  
Location 
Rural 937 146 160.0(131.9,192.8) Baseline p=0.55  
Urban 345 56 171.2(116.8,244.0) 1.1(0.8,1.7)  
SES Quartile (7 missing values) 
Lower 266 50 216.0(154.0,294.2) Baseline p=0.07  
Lower middle 347 43 128.5(94.4,172.4) 0.6(0.4,0.9)  
Upper middle 345 59 169.1(128.1,219.8) 0.8(0.5,1.3)  
Upper 317 48 148.5(105.9,204.4) 0.7(0.5,1.1)  
Smoker 
Never 861 142 173.6(141.6,211.1) Baseline p=0.12  
Former 104 9 83.5(39.5,167.9) 0.5(0.2,1.0)  
Current 317 51 165.7(125.5,215.7) 0.9(0.7,1.2)  
Hypertension (2 missing values) 
No 664 95 149.1(113.3,193.6) Baseline p=0.37  
Yes 616 106 178.0(143.1,219.2) 1.2(0.8,1.6)  
Diabetic (1 missing value) 
No 1223 188 157.8(131.7,187.9) Baseline p=0.07 Baseline p=0.04 
Yes 58 14 263.9(136.3,448.9) 1.7(1.0,2.8) 1.7 (1.0,2.8) 
Alcohol (2 missing values) 
Never 524 85 171.6(133.7,217.5) Baseline p=0.59  
Former 549 81 155.2(117.5,202.2) 0.8(0.6,1.2)  
Current 207 36 169.6(116.3,240.6) 1.0(0.6,1.4)  
Ethnic group 
Kikuyu 799 126 164.7(130.5,205.6) Baseline p=0.51  
Kalenjin 324 46 148.5(107.4,201.7) 0.9(0.6,1.3)  
Other 159 30 184.4(119.2,274.3) 1.2(0.8,2.0)  
Education level (1 missing value) 
No education 119 12 111.3(58.2,202.5) Baseline p=0.16  
Primary 345 66 215.8(161.8,281.7) 1.8(0.9,3.4)  
Secondary 677 104 152.8(123.7,187.4) 1.3(0.7,2.5)  
College/Uni 140 20 128.5(80.7,198.4) 1.2(0.5,2.6)  
 27 
*For multivariable analysis, an initial model was fitted that included those variables shown to be associated with 
outcome in age-adjusted analysis (using a Wald test threshold p-value of <0.05 to indicate association). A 
backward stepwise approach was then applied in order to obtain a final multivariable model, removing variables 
with p>0.05 one-by-one. 
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